<DOC>
	<DOC>NCT02902640</DOC>
	<brief_summary>This is a pilot, observational and multicentric study of safety of sulfamethoxazole plus (+) trimethoprim + guaifenesin (Balsamic Bactrim) in adult participants with acute bronchitis. Overall, 50 adult participants with acute bronchitis eligible for treatment with sulfamethoxazole + trimethoprim + guaifenesin will be enrolled. Administration of Balsamic Bactrim will be according to physician's recommendation under local labeling.</brief_summary>
	<brief_title>An Observational Study to Assess Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Adult Participants With Acute Bronchitis</brief_title>
	<detailed_description />
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
	<criteria>Participants starting treatment with Balsamic Bactrim as per treating physician's discretion Participants with a clinical diagnosis of acute bronchitis (Cough with or without sputum production less than 30 days) Participants who have started treatment with another antibiotic at the time of the visit Participants with no respiratory infections Participants with mental disorders Participants with severe hepatic parenchymal damage Participants with severe renal failure if the drug plasma concentration cannot be monitored Participants with hypersensitivity to any of its active ingredients or excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>